Yes a CR would be dilutive. But look at the reward it would bring market cap wise if the trial goes to plan. This more than makes up for any dilution now. And this is only considering DMD.
This trial, when done and if sucessful, opens a non diluting funding stream into all the other indications.
So there are plenty of positives for both CR and partnership.
Company making times at the moment.
Yes a CR would be dilutive. But look at the reward it would...
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.0¢ |
Change
0.006(9.38%) |
Mkt cap ! $62.20M | |||
| Open | High | Low | Value | Volume |
| 6.6¢ | 7.1¢ | 6.5¢ | $124.8K | 1.809M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3077 | 6.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.0¢ | 17568 | 1 |
View Market Depth
| Last trade - 14.38pm 26/04/2024 (20 minute delay) ? |
|
|||||
|
Last
7.0¢ |
Change
0.006 ( 17.7 %) |
||||
| Open | High | Low | Volume | ||
| 6.6¢ | 7.1¢ | 6.6¢ | 244114 | ||
| Last updated 14.38pm 26/04/2024 ? | |||||
| PER (ASX) Chart |